Index S&P 500
P/E 27.39
EPS (ttm) 3.29
Insider Own 0.12%
Shs Outstand 1.28B
Perf Week -3.45%
Market Cap 115.60B
Forward P/E 15.45
EPS next Y 5.83
Insider Trans -1.43%
Shs Float 1.28B
Perf Month 0.21%
Income 4.26B
PEG 4.17
EPS next Q 1.58
Inst Own 85.00%
Short Float 1.05%
Perf Quarter 12.62%
Sales 33.20B
P/S 3.48
EPS this Y 4.88%
Inst Trans 1.13%
Short Ratio 1.81
Perf Half Y 0.74%
Book/sh 38.49
P/B 2.34
EPS next Y 6.93%
ROA 4.71%
Short Interest 13.49M
Perf Year 7.25%
Cash/sh 6.18
P/C 14.59
EPS next 5Y 6.57%
ROE 8.42%
52W Range 75.96 - 96.25
Perf YTD 12.83%
Dividend Est. 2.70 (3.00%)
P/FCF 21.14
EPS past 5Y -4.12%
ROI 5.81%
52W High -6.36%
Beta 0.82
Dividend TTM 2.10 (2.33%)
Quick Ratio 1.43
Sales past 5Y 1.24%
Gross Margin 60.32%
52W Low 18.65%
ATR (14) 1.79
Dividend Ex-Date Mar 28, 2025
Current Ratio 1.90
EPS Y/Y TTM 4.48%
Oper. Margin 18.65%
RSI (14) 44.37
Volatility 1.70% 1.92%
Employees 95000
Debt/Eq 0.54
Sales Y/Y TTM 2.72%
Profit Margin 12.83%
Recom 2.39
Target Price 95.48
Option/Short Yes / Yes
LT Debt/Eq 0.49
EPS Q/Q 1.35%
Payout 99.87%
Rel Volume 0.73
Prev Close 90.33
Sales Surprise -0.42%
EPS Surprise 2.23%
Sales Q/Q 2.51%
Earnings Feb 18 BMO
Avg Volume 7.47M
Price 90.13
SMA20 -2.35%
SMA50 -0.35%
SMA200 4.62%
Trades
Volume 5,420,318
Change -0.22%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-04-25 Upgrade
Citigroup
Neutral → Buy
$92 → $107
Oct-10-24 Upgrade
RBC Capital Mkts
Sector Perform → Outperform
$98 → $105
Aug-21-24 Reiterated
Oppenheimer
Perform
$92 → $94
Aug-15-24 Upgrade
UBS
Sell → Neutral
$76 → $90
Aug-14-24 Downgrade
Stifel
Buy → Hold
$100 → $85
May-30-24 Initiated
Goldman
Sell
$83
Jul-19-23 Initiated
Robert W. Baird
Neutral
$90
Jun-30-23 Initiated
CL King
Buy
$106
May-30-23 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$104
Apr-24-23 Upgrade
Wells Fargo
Equal Weight → Overweight
$77 → $100
Mar-29-23 Downgrade
UBS
Buy → Sell
$127 → $79
Jan-09-23 Downgrade
RBC Capital Mkts
Outperform → Sector Perform
$102 → $89
Nov-23-22 Downgrade
Oppenheimer
Outperform → Perform
$106 → $85
Nov-23-22 Downgrade
Citigroup
Buy → Neutral
$108 → $85
Nov-16-22 Downgrade
Deutsche Bank
Buy → Hold
$85
Oct-18-22 Initiated
Barclays
Equal Weight
$90
Oct-13-22 Initiated
Mizuho
Buy
$100
Oct-12-22 Initiated
Jefferies
Hold
$87
Aug-24-22 Downgrade
Raymond James
Outperform → Mkt Perform
Jul-06-22 Initiated
Wolfe Research
Underperform
$85
Show Previous Ratings
Today 03:09AM
Mar-24-25 12:00PM
08:45AM
Mar-22-25 12:31AM
Mar-21-25 04:43PM
02:04PM
Loading…
Mar-20-25 02:04PM
11:30AM
11:20AM
09:40AM
08:23AM
Mar-19-25 09:41PM
01:10PM
11:03AM
09:00AM
06:16AM
09:50AM
Loading…
Mar-18-25 09:50AM
08:50AM
Mar-17-25 12:01PM
Mar-12-25 03:05AM
Mar-11-25 03:50PM
Mar-10-25 06:14AM
05:21AM
04:36AM
Mar-09-25 05:15PM
02:00PM
Mar-07-25 08:17AM
(Thomson Reuters StreetEvents)
08:15AM
Mar-06-25 04:30PM
Mar-05-25 09:45AM
Mar-04-25 11:22AM
02:01PM
Loading…
Mar-03-25 02:01PM
12:15PM
06:18AM
Feb-28-25 10:00AM
Feb-27-25 07:27AM
05:30AM
(The Wall Street Journal)
Feb-26-25 02:48PM
Feb-25-25 02:52PM
(Investor's Business Daily)
09:06AM
06:38AM
01:21AM
Feb-24-25 12:48PM
11:45AM
09:00AM
07:30AM
07:13AM
Feb-21-25 11:21AM
09:36AM
Feb-20-25 10:17AM
04:45AM
Feb-19-25 06:23AM
02:03AM
Feb-18-25 04:48PM
(Investor's Business Daily) -7.26%
01:54PM
01:08PM
01:08PM
12:30PM
12:08PM
11:16AM
11:06AM
09:30AM
09:30AM
08:43AM
07:55AM
07:23AM
07:14AM
06:51AM
(Associated Press Finance)
06:45AM
Feb-14-25 08:00AM
(The Wall Street Journal)
Feb-13-25 05:45PM
05:30AM
04:38AM
Feb-12-25 11:34AM
09:15AM
08:49AM
Feb-11-25 12:30PM
Feb-10-25 12:55PM
12:40PM
Feb-07-25 05:45PM
Feb-06-25 06:42AM
Feb-05-25 05:50PM
05:08PM
10:44AM
10:39AM
08:00AM
Feb-04-25 11:09AM
Feb-01-25 08:41AM
Jan-30-25 05:50PM
05:12AM
Jan-29-25 05:00AM
Jan-28-25 09:45AM
06:09AM
Jan-27-25 06:27AM
Jan-25-25 12:15PM
09:11AM
Jan-24-25 05:50PM
12:00PM
Jan-23-25 11:37PM
12:42PM
Jan-22-25 01:08PM
Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Walter Matthew R. SVP, Chief HR Officer Jan 27 '25 Option Exercise 74.84 1,337 100,061 26,997 Jan 28 05:10 PM Marinaro Michael EVP & President, Surgical OU Jan 27 '25 Option Exercise 74.84 2,345 175,500 43,323 Jan 28 05:09 PM Martha Geoffrey Chairman and CEO Jan 27 '25 Option Exercise 74.84 34,741 2,600,016 216,954 Jan 28 05:07 PM Wall Brett A. EVP & Pres Neuroscience Jan 24 '25 Option Exercise 78.00 12,437 970,086 53,416 Jan 27 05:35 PM Wall Brett A. EVP & Pres Neuroscience Jan 24 '25 Sale 90.00 12,437 1,119,330 40,979 Jan 27 05:35 PM Wall Brett A. Officer Jan 24 '25 Proposed Sale 90.00 12,437 1,119,330 Jan 24 02:34 PM Wall Brett A. EVP & Pres Neuroscience Jan 08 '25 Option Exercise 74.84 6,850 512,654 50,558 Jan 10 04:48 PM Wall Brett A. EVP & Pres Neuroscience Jan 08 '25 Sale 80.41 9,850 792,038 40,708 Jan 10 04:48 PM Wall Brett A. Officer Jan 08 '25 Proposed Sale 80.41 9,850 792,038 Jan 08 09:52 AM PARKHILL KAREN L Former Director Oct 31 '24 Proposed Sale 89.73 30,000 2,691,794 Oct 31 03:21 PM PARKHILL KAREN L Former Director Oct 30 '24 Proposed Sale 90.58 15,000 1,358,740 Oct 30 04:11 PM PARKHILL KAREN L Former BOD Oct 29 '24 Proposed Sale 91.16 15,000 1,367,348 Oct 29 03:26 PM PARKHILL KAREN L Former Director Oct 24 '24 Proposed Sale 92.49 22,712 2,100,633 Oct 24 04:01 PM PARKHILL KAREN L Former Director Oct 23 '24 Proposed Sale 91.76 23,848 2,188,205 Oct 23 04:30 PM PARKHILL KAREN L Former BOD Oct 18 '24 Proposed Sale 91.74 48,825 4,479,310 Oct 18 04:24 PM PARKHILL KAREN L Former BOD Oct 17 '24 Proposed Sale 89.87 55,179 4,958,718 Oct 17 03:35 PM PARKHILL KAREN L Former Officer Aug 26 '24 Proposed Sale 90.00 2,668 240,120 Aug 26 02:11 PM Wall Brett A. EVP & Pres Neuroscience Aug 02 '24 Option Exercise 0.00 5,311 0 49,169 Aug 06 06:16 PM Walter Matthew R. SVP, Chief HR Officer Aug 02 '24 Option Exercise 0.00 684 0 25,889 Aug 06 06:15 PM Smith Gregory L EVP Global Ops & Supply Chain Aug 02 '24 Option Exercise 0.00 3,490 0 64,757 Aug 06 06:14 PM Salmon Sean EVP & President Cardiovascular Aug 02 '24 Option Exercise 0.00 5,462 0 68,546 Aug 06 06:14 PM PARKHILL KAREN L EVP & Chief Financial Officer Aug 02 '24 Option Exercise 0.00 7,132 0 53,459 Aug 06 06:13 PM Martha Geoffrey Chairman and CEO Aug 02 '24 Option Exercise 0.00 18,966 0 203,086 Aug 06 06:13 PM Marinaro Michael EVP & President, Surgical OU Aug 02 '24 Option Exercise 0.00 1,670 0 43,801 Aug 06 06:12 PM Kirk Jennifer M Chief Accounting Officer Aug 02 '24 Option Exercise 0.00 1,138 0 28,980 Aug 06 06:12 PM Fong Ivan K EVP GENERAL COUNSEL & SECR Aug 02 '24 Option Exercise 0.00 14,514 0 63,750 Aug 06 06:11 PM Walter Matthew R. SVP, Chief HR Officer Jul 18 '24 Option Exercise 62.76 492 30,878 17,580 Jul 19 04:40 PM Martha Geoffrey Chairman and CEO Jun 07 '24 Option Exercise 62.76 19,113 1,199,532 162,461 Jun 11 06:53 PM Martha Geoffrey Chairman and CEO Jun 07 '24 Sale 83.77 19,113 1,601,001 143,348 Jun 11 06:53 PM Marinaro Michael EVP & President, Surgical OU Apr 08 '24 Sale 83.14 854 71,002 27,925 Apr 09 04:08 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite